1. Aydinok Y. Thalassemia. Hematology 2012;17(sup1):s28-s31. https://doi.org/10.1179/102453312X13336169155295

2. Goh LPW, Chong ETJ, Lee P-C. Prevalence of Alpha(α)-Thalassemia in Southeast Asia (2010–2020): A Meta-Analysis Involving 83,674 Subjects. Int J Environ Res Public Health 2020;17(20):7354. https://doi.org/10.3390/ijerph17207354

3. Sayani FA, Kwiatkowski JL. Increasing prevalence of thalassemia in America: Implications for primary care. Ann Med 2015;47(7):592-604. https://doi.org/10.3109/07853890.2015.1091942

4. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5(1):11. https://doi.org/10.1186/1750-1172-5-11

5. Joly P, Lacan P, Garcia C, Couprie N, Francina A. Identification and molecular characterization of four new large deletions in the β-globin gene cluster. Blood Cells Mol Dis 2009;43(1):53-7. https://doi.org/10.1016/j.bcmd.2009.01.017

6. Li Y, Ren Q, Zhou Y, Li P, Lin W, Yin X. Thalidomide has a significant effect in patients with thalassemia intermedia. Hematology 2018;23(1):50-4. https://doi.org/10.1080/10245332.2017.1354427

7. Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood Rev 2019;37:100588. https://doi.org/10.1016/j.blre.2019.100588

8. Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil J-A, Hongeng S, et al. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. New Eng J Med 2018;378(16):1479-93. https://doi.org/10.1056/NEJMoa1705342

9. Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, et al. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. New Eng J Med 2020;382(13):1219-31. https://doi.org/10.1056/NEJMoa1910182

10. Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion 2014;54(4):972-81. https://doi.org/10.1111/trf.12348

11. Chen J-M, Zhu W-J, Liu J, Wang G-Z, Chen X-Q, Tan Y, et al. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial. Signal Transduct Target Ther 2021;6(1):405. https://doi.org/10.1038/s41392-021-00811-0

12. Zhu W, He Y, Huang M. Long-term follow-up of patients undergoing Thalidomide Therapy for transfusion-dependent β-Thalassaemia: A Single-Center Experience. Int J Gen Med 2024;17:1729-38. https://doi.org/10.2147/ijgm.s462991

13. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Med 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097

14. NIH. (National Institute of Health). Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group 2021 [Accessed on: May 20, 2024]. Available from URL: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.

15. Bhattacharjee U, Khadwal A, Shafiq N, Lad D, Sharma P, Das R, et al. A Phase 2 Randomized Controlled Trial of Single-Agent Hydroxyurea Versus Thalidomide Among Adult Transfusion Dependent β Thalassemia Patients. Indian J Hematol Blood Trans 2023;39(2):266-75. https://doi.org/10.1007/s12288-022-01620-3

16. Ali Z, Ismail M, Rehman IU, Rani GF, Ali M, Khan MTM. Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study. Sci Rep 2023;13(1):13592. https://doi.org/10.1038/s41598-023-40849-4

17. Li X, Hu S, Liu Y, Huang J, Hong W, Xu L, et al. Efficacy of Thalidomide Treatment in Children With Transfusion Dependent β-Thalassemia: A Retrospective Clinical Study. Front Pharmacol 2021;12. https://doi.org/10.3389/fphar.2021.722502

18. Chandra J, Parakh N, Sidharth, Singh N, Sharma S, Goel M, et al. Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia. Indian Pediatr 2021;58(7):611-6.

19. Yassin AK. Promising Response to Thalidomide in Symptomatic β-Thalassemia. Indian J Hematol Blood Trans 2020;36(2):337-41. https://doi.org/10.1007/s12288-019-01231-5

20. Nag A, Radhakrishnan VS, Kumar J, Bhave S, Mishra DK, Nair R, et al. Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience. Indian J Hematol Blood Trans 2020;36(2):399-402. https://doi.org/10.1007/s12288-020-01263-2

21. Yang K, Wu Y, Ma Y, Xiao J, Zhou Y, Yin X. The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients. Blood Cells Mol Dis 2020;84:102442. https://doi.org/10.1016/j.bcmd.2020.102442

22. Yang K, Wu Y, Zhou Y, Long B, Lu Q, Zhou T, et al. Thalidomide for Patients with β-Thalassemia: A Multicenter Experience. Mediterr J Hematol Infect Dis 2020;12(1):e2020021. https://doi.org/10.4084/mjhid.2020.021

23. Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients. Exp Rev Hematol 2018;11(6):471-9. https://doi.org/10.1080/17474086.2018.1476134

24. Faranoush P, Jahandideh A, Nekouian R, Mortazavi P. Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research. Vet Med Sci 2023;9(3):1426-37. https://doi.org/10.1002/vms3.1109

25. Fleming RE, Ponka P. Iron Overload in Human Disease. New Eng J Med 2012;366(4):348-59. https://doi.org/10.1056/NEJMra1004967

26. Lekawanvijit S, Chattipakorn N. Iron overload thalassemic cardiomyopathy: Iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Canadian J Cardiol 2009;25(4):213-8. https://doi.org/10.1016/S0828-282X(09)70064-9

27. Wijarnpreecha K, Kumfu S, Chattipakorn SC, Chattipakorn N. Cardiomyopathy Associated with Iron Overload: How Does Iron Enter Myocytes and What are the Implications for Pharmacological Therapy? Hemoglobin 2015;39(1):9-17. https://doi.org/10.3109/03630269.2014.987869

28. Bellotti D, Remelli M. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules 2021;26(11):3255. https://doi.org/10.3390/molecules26113255

29. Aguilar-Lopez LB, Delgado-Lamas JL, Rubio-Jurado B, Javier Perea F, Ibarra B. Thalidomide therapy in a patient with thalassemia major. Blood Cells Mol Dis 2008;41(1):136-7. https://doi.org/10.1016/j.bcmd.2008.03.001

30. Mallik S, Chatterjee C, Mandal PK, Sardar JC, Ghosh P, Manna N. Expenditure to treat thalassaemia: an experience at a tertiary care hospital in India. Iranian J Public Health. 2010;39(1):78-84.

31. Uchil A, Muranjan M, Gogtay NJ. Economic burden of beta-thalassaemia major receiving hypertransfusion therapy at a public hospital in Mumbai. Natl Med J India 2023;36(1):11-6. https://doi.org/10.25259/NMJI_580_20

32. Reed-Embleton H, Arambepola S, Dixon S, Maldonado BN, Premawardhena A, Arambepola M, et al. A cost-of-illness analysis of β-Thalassaemia major in children in Sri Lanka – experience from a tertiary level teaching hospital. BMC Pediatr 2020;20(1):257. https://doi.org/10.1186/s12887-020-02160-3